Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Asthma J.B. Handler, M.D. Physician Assistant Program University of New England 1 Abbreviations SOB-shortness of breath ASA- aspirin P.E.- physical exam EOS- eosinophils RR- respiratory rate ABG- arterial blood gas Nl- normal CxR- chest x-ray SaO2- saturation of oxygen OP- out patient V/Q- ventilation/perfusion DM- diabetes mellitus ß- beta EIA-exercise induced asthma PRN- as needed HTN- hypertension D/C- discontinue SO2- sulfate NO2- nitrate GERD- gastroesophageal reflux disease PO- by mouth Alt- alternative NSAID- non-steroidal antiinflammatory drug 2 Definition A clinical syndrome of unknown etiology with three components: 1. Recurrent episodes of airway obstruction that resolve spontaneously or following treatment. 2. Exaggerated bronchoconstrictor response to stimuli that have little/no effect on non-asthmatics. 3. Inflammation of the airways. 3 Case 1 A 45 y/o white male presents with paroxysms of severe coughing lasting up to 1 hour, resolving spontaneously. He had a recent URI. No prior history of pulmonary problems. No hx of smoking. Currently feels well. P.E: Healthy appearing male, NAD; Vesicular breath sounds throughout both lung fields without wheezing, ronchi or crackles. What is your differential diagnosis? 4 Differential Diagnosis New/superimposed respiratory infection- bronchitis, pertussis, etc. Asthma Allergies Toxin or pollutant exposure Early signs of new disease Psychogenic cough – dx only of exclusion 5 Epidemiology 5% of child/adult U.S. population Can develop any time in life (often <25 y.o.) 500,000 hospitalizations, 5,000 deaths/yr. 15 million OP visits/yr. >6 billion dollars/annually 6 Pathogenesis Genetic predisposition. Inflammatory infiltrates (lymphocytes, neutrophils, eosinophils, mast cells). Injury to airway epithelium; denudation. Thickened airway wall from: Inflammation, collagen deposition, smooth muscle hypertrophy. Hypertrophy and hyperplasia of airway glands. Airway hyperresponsiveness. 7 Pathogenesis Episodic airway narrowing: smooth muscle constriction, thickening of airway epithelium and mucus secretion into the airway lumen; mucus inspissates. Local release of bioactive mediators or neurotransmitters during attacks contributes to airway constriction. End result is acute, reversible obstruction of the airway lumen to airflow. 8 Pathophysiology Airway resistance; medium and small airwayswork of breathing. Diffuse airway obstruction. Airway reactivity to variety of stimuli. V/Q mismatch: low V/Q contributes to hypoxemia when present. Tachypnea results in PCO2. If PCO2, ominous sign of ventilatory failure. 9 Airway Obstruction AllRefer Health Asthma Microscopic Images.google.com Asthma: Mucous Plugging Mediators: Acute Response Acetylcholine: neurotransmitter released via intrapulmonary branches of vagus nerve increases bronchial smooth muscle contraction bronchoconstriction. Histamine: endogenous bronchoconstrictor in mast cells, basophils, lungs. Vasodilator properties promote capillary leakage in presence of inflammation. 13 Mediators: Acute Response Kinins- bradykinin activated by enzymes (kallikreins) released by mast cells- bronchoconstrictor. Leukotrienes: biochemical mediators released by mast cells, EOS and macrophages-potent smooth muscle constriction; increase mucus secretion and activate airway inflammatory cells. 14 Asthma Triggers “Atopy” association of allergies- inhaled allergens can trigger attacks- dust mites, cats, seasonal pollens, hay fever, etc. Single largest risk factor for developing asthma. Non-specific triggers: URI’s, sinusitis, tobacco smoke, ozone, GERD, weather, stress, exercise, SO2, NO2, and others. Aspirin allergy- cross reactivity with other NSAIDs, but not selective COX-2 agents. Absence of triggers not unusual as well. 15 Clinical Presentation History: “attacks” of coughing, wheezing, SOB, anxiety, chest tightness. Associations- allergies, irritants, ASA. Highly variable presentation. Episodes often at night and early AM when airway reactivity is highest. P.E*: P & RR, secretions, expiratory phase, wheezing, mucosal swelling. Note: with severe asthma, wheezing may decrease or stopdecreased airflow. *During asthma episode/attack 16 Pulmonary Function Testing Spirometry easily obtainable – FVC, FEV1, FEV1/FVC. PEFR-Peak expiratory flow rate-(L/min)varies with age, gender, height; handheld device good for following asthma severity as an adjunct to PFT’s. Spirometry or PEFR following bronchodilator: assess responsiveness to treatment. 17 Spirometry of Asthmatic Lung volumes: TLC, FRC, RV; FVC normal or slightly Lung flow:; FEV1, FEV1/FVC (<70% means obstruction), PEFR. DLCO- normal Spirometry in between asthmatic attacks may or may not be normal; depends on asthma severity/classification (see below). 18 Case 1 One year ago, he had a similar episode which responded to antibiotics. In the last year he has noted episodic coughing when using a dictaphone or speaking for extended periods of time. Some episodes with exercise- no pattern. PFT’s done on 2 occasions when asymptomatic have been entirely normal. Symptoms rapidly respond to short courses of oral prednisone. 19 Pulmonary Testing Provocative testing (If spirometry nl)Methacholine challenge to induce Sx and decrease in FEV1 (by 20% or more). If negative, asthma very unlikely. Arterial blood gases (ABG’s)- measure pH, PCO2, PO2. Respiratory Alkalosis with PCO2 is common during attack. If PCO2 is normal or high during an attack impending respiratory failure. PO2 indicates severe V/Q mismatch. CxR- Often normal vs hyperinflation. 20 Case 1 During methacholine challenge testing, he has abrupt onset of severe coughing with a >20% drop in FEV1 and FEV1/FVC. Treatment with inhaled ß-agonist aborts the attack. PFT’s return to normal following albuterol. 21 Asthma Complications Infection including pneumonia Exhaustion, dehydration Oxygenation failure Ventilation failure – lose drive to inflate alveoli Death 22 Classification of Severity Applies to clinical features of chronic, stable asthma. Mild intermittent asthma - Symptoms 2x/week - No symptoms and normal PEFR between attacks - Night symptoms 2x/month - FEV1 and PEFR 80% predicted* - PEFR variability 20% *In between attacks Current, Chapter 9 23 Mild persistent asthma - Symptoms > 2x/week, <1x/day - Night symptoms > 2x/month - FEV1 or PEFR 80% predicted* - PEFR variability 20-30% *In between attacks Current, Chapter 9 24 Moderate persistent asthma - Daily symptoms; daily use of inhaled short acting ß2 agonists - Night symptoms >1x/week - FEV1 or PEFR >60% to <80% * predicted - PEFR variability >30% *In between attacks Current, Chapter 9 25 Severe persistent asthma - Symptoms daily and frequent- may be continuous - Frequent night symptoms - FEV1 or PEFR 60% predicted* - PEFR variability >30% Note: Exacerbations of symptoms are common in patients with asthma and often limit activities in moderate to severe forms. *In between attacks Current, Chapter 9 26 Long Term Treatment Goals Minimize chronic symptoms that impair normal activity. Minimize exacerbations/hospitalizations. Limit side effects of medications. Cornerstone treatment of persistent asthma- daily anti-inflammatory therapy with inhaled corticosteroids. Stepped care approach (Current, table 93). Long term control vs. quick relief meds. 27 Quick Relief: Beta Adrenergic Agents Most efficacious brondchodilators for acute symptoms. Also used to prevent exercise induced asthma (EIA). 2 agonists selectively relax bronchial smooth musclebronchodilate while limiting cardiac stimulation. 28 Quick Relief: Beta Adrenergic Agents Albuterol, others: Rapid onset of action (<5”); most effective agents for acute bronchospasm. Use of a spacer may improve delivery. MDI 1-2 puffs (0.18mg) up to 6+ puffs q6hr; delivery may improve with spacer. Nebulizer doses (2.5 mg) are 14x more potent than MDI (2 inhalations)- more effective for severe asthmatic exacerbations (ED, hospitalized). 29 Inhalers and Spacers AllRefer Health Quick Relief: Anticholinergic Meds Reverse vagally mediated bronchoconstriction and mucus production. Ipratropium bromide (Atrovent) via inhaler 2-4 puffs (18mcg/puff) q6h as an alternative or adjunct (in moderate to severe exacerbations) to short acting Bagonists; not as effective. Not useful for EIA or allergy induced asthma 31 Long Term Control: Inhaled Corticosteroids Low to high dose, local Corticosteroids: most important and effective for long term control in persistent asthma. Reduce chronic and acute inflammation; mild persistent asthma and worse. Inhaled preparations for prevention; dose titrated to symptom relief; may take weeks for optimal efficacy; adrenal suppression unlikely. 32 Inhaled Corticosteroids Several agents- varying potency (Fluticasone, Beclomethazone, Flunisolide et. al.). Usually 2x or 3x daily dosing Follow by H2O or mouth wash gargle to avoid local yeast (Candida) infection. 33 Long Term Control: Long Acting -agonists Used for long term (8-12 hrs) bronchodilation and EIA; not for acute episodes. Especially beneficial for night time symptoms. Salmeterol (Serevent): 50mcg 2x/d. Formoterol is new with similar effects. 34 Salmeterol Safety Concerns Two large clinical trials salmeterol s asthma exacerbations and asthma related deaths (small number of patients, but statistically significant). Black-box warning on labeling since 2005 Little change in prescribing since. Message: Use with caution. Confine use only to patients already on inhaled corticosteroids with ongoing symptoms. 35 Leukotriene Modifiers Leukotriene modifiers: Inhibit synthesis (Zileuton/Zyflow) or action (Zafirlukast/Accolade) of leukotrienes; inhibit inflammatory mediators; decreases need for rescue inhaler. Modest efficacy for patients with mild persistent asthma. Alternative to low dose inhaled steroids in treatment of mild persistent asthma. 36 Mediator Inhibitors Chromolyn, Nedocromil- mild improvement in airway function in mild persistent or EIA. Inhibit mast cell release of mediators of inflammation; inhibit asthmatic response to allergens. Alternative to IC for some patients with mild persistent asthma and allergies. Limited usefullness. Excellent safety profile 37 Systemic Corticosteroids Systemic steroids are used in Rx of moderate to severe asthma exacerbations; marked antiinflammatory properties speed (6+ hours) the resolution of airway obstruction and reduce rate of relapse; oral or IV dosing. Long term use may be required in some patients with severe persistent asthma. 38 Systemic Corticosteroids Prednisone et. al. (40-60 mgs/daily for out-patient care); higher doses required if severity requires hospitalization. Safe when used for short term treatment (see below) of moderate to severe exacerbations. May occasionally be needed (short term course) in some patients with mild asthma during severe exacerbations. 39 Systemic Corticosteroids Dangers: Supraphysiologic dosing over time leads to long term risks: Adrenal suppression, HTN, osteoporosis, glucose intolerance/DM, easy bruisability, weight gain, etc. Goal: Pulse dosing followed by taper and D/C, overlapping with dosing of inhaled agents which have minimal systemic side effects. Tapering dose (days to weeks) allows return of adrenal-pituitary axis. 40 Interest Only Phosphodiesterase inhibitorsaminophylline, theophylline- less effective and potentially toxic; adjunctive Rx for mod to severe persistent asthma. Toxicity- Low therapeutic/toxic ratio- GI (nausea, abd. pain), CNS stimulation (anxiety, HA,tremors, seizures)and Cardiac (arrhythmias, tachycardia). Must monitor serum theophylline levels to maintain therapeutic range (10-20 ug/ml). 41 Still Other……IO Oral -agonists- terbutaline, albuterol tablets- usually add little to inhaled agents; may be useful as an adjunct; terbutaline causes tremors. Immunosuppresive agents: Methotrexate, cyclosporine, trolandomycin- for patients unresponsive to other drugs or where steroids contraindicated. 42 Combination Meds Advair Diskus: Combination inhaler with Fluticasone in varying strengths combined with a fixed dose (50mcg) of Salmeterol, one inhalation b.i.d, decreases number of inhalers and inhalations. Combivent: Albuterol + ipratropium 43 Case 1: Many Years Later He remains asymptomatic and has reduced meds over time. Rare coughing episodes rapidly respond to albuterol inhaler. Meds: Fluticasone MDI 220mcg 2x/d Abuterol MDI (90mcg/puff)- 2-3 puffs prn Notes breathing is best when teaching PA students at UNE! 44 Mild Persistent Asthma Long Term Control: Daily meds Either low dose inhaled steroid or Cromolyn/Nedocromil Alternative: Leukotriene modifier Quick Relief: Short acting B2 agonist Frequent or increasing use of B2 agonist suggests need for additional therapy. If needed increase dose of IC’s Current, Chapter 9 45 Moderate Persistent Asthma Long Term Control: Daily meds Low, medium or high dose inhaled streroid If needed, add long acting bronchodilator -B2 agonist (esp for night time Sx) Quick Relief: Short acting inhaled B2 agonist Frequent or increasing use of B2 suggests need for additional therapy Alt: SR theophylline Current, Chapter 9 46 Severe Persistent Asthma Long Term Control: Daily meds High dose inhaled corticosteroid Long acting bronchodilator -B2 agonist Alt: SR theophylline Quick Relief: Short acting B2 agonist Frequent or increasing use of B2 suggests need for additional therapy Oral steroid therapy often needed for long periods. Current, Chapter 9 47 Mild Asthma Exacerbations Stepped care incremental therapy Most are treated at home with quick response to ’d dose/frequency of short acting “rescue” ß-agonist. These drugs may be needed every 3-6 hours for a short course. Inhaled corticosteroids may need to be added (*MIA) or dose ’d (x2) if already taken (*PA); full effect will take weeks. *MIA- mild intermittent asthma *PA- persistent asthma 48 Mild Asthma Exacerbations If already taking an inhaled corticosteroid, the dose is doubled during an acute exacerbation until PEFR return to normal. If unresponsive, an oral systemic corticosteroid may be needed for a short course, then tapered, returning to inhaled corticosteroids. 49 Moderate/Severe Attacks Some patients (caution) managed as out patient- require very close monitoring via phone. Most patients warrant hospitalization. Supplemental O2 as needed to maintain SaO2>90%. Continuous O2 saturation monitoring via oximetry if hospitalized. 50 Moderate/Severe Attacks Reversal of airway obstructionrepetitive/continuous use of high dose ß-agonists usually via nebulizer. Early administration of systemic corticosteroids IV; high dose. Serial measurement of lung function: PEFR or spirometry to monitor course. ABG’s often helpful: pH, PO2, PCO2. 51 Moderate/Severe Attacks Never sedate during acute asthma exacerbation; will ventilatory drive. Dropping PO2 <60mm Hg (O2 sat<90%) and rising PCO2> 42mm Hg are evidence of impending respiratory/ventilatory failure and warrant treatment in the ICU. Intubation may be required- initiate before patient has respiratory arrest. 52 Moderate/Severe Attacks Rehydration IV usually warranted- BP will drop once on ventilator. Bronchodilators are maintained on ventilator. IV Magnesium Sulfate has some usefulness for bronchial relaxation. Once improved, discharge considered once FEV1 or PEFR70% of predicted or personal best. 53